Non-Hodgkins Lymphoma / T-Cell Lymphoma
A Phase II Placebo-Controlled Study of Photodynamic Therapy With Topical Hypericin and Visible Light Irradiation in the Treatment of Cutaneous T-cell Lymphoma and Psoriasis
Results: After 6 weeks of twice-weekly therapy, several concentrations of hypericin resulted in the significant improvement of treated skin lesions among the majority of patients with cutaneous T-cell lymphoma and psoriasis whereas the placebo vehicle was ineffective.
Limitations: The clinical trial involved a small number of patients.
Conclusions: Overall, the data from this study support the conclusion that topical hypericin/visible light photodynamic therapy is an effective and well-tolerated alternative to standard psoralen plus ultraviolet A treatment of these disorders